Drug Type Degradable Molecular Glue |
Synonyms CDK2 Molecular Glue Ddegrader(Plexium), CDK2 bivalent degrader(Plexium) |
Target |
Action inhibitors |
Mechanism CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CRBN inhibitors(Cereblon inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | Preclinical | United States | 29 Apr 2025 | |
Endometrial Carcinoma | Preclinical | United States | 08 Jun 2024 | |
Ovarian Cancer | Preclinical | United States | 08 Jun 2024 | |
ER-positive/HER2-negative Breast Cancer | Discovery | United States | 05 Jan 2024 |